Antigenics launches phase I study for newly formulated Aroplatin

By E. Janene Geiss

Philadelphia, Oct. 25 - Antigenics Inc. announced Tuesday that it has initiated a multicenter phase I clinical trial of Aroplatin, an investigational formulation of a proprietary platinum chemotherapeutic.

The protocol calls for enrollment of 16 to 28 patients with advanced solid malignancies or B-cell lymphoma. Based on safety assessment and preliminary clinical activity, Antigenics expects to implement a clinical development plan to further investigate Aroplatin in multiple cancers.

The dose-ranging study will evaluate the safety and pharmacokinetic profile of Aroplatin, which has been reformulated to enhance the drug's activation and stability, according to a company news release.

"The launch of the phase I trial of the new Aroplatin reflects Antigenics' growing presence in oncology as well as the continued strength and versatility of our pipeline," Renu Gupta, senior vice president of development for Antigenics, said in the release.

Aroplatin is novel, third-generation liposome-encapsulated platinum compound developed for the treatment of cancer.

Antigenics is a New York City-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.